Clinical Trials Logo

Recurrent Platinum Resistant Ovarian Cancer clinical trials

View clinical trials related to Recurrent Platinum Resistant Ovarian Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT02889900 Recruiting - Clinical trials for Recurrent Platinum Resistant Ovarian Cancer

Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer

CONCERTO
Start date: January 17, 2017
Phase: Phase 2
Study type: Interventional

This is an open label, single arm, multi-center study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in platinum-resistant relapsed high grade serous, high grade endometroid or clear cell ovarian, fallopian tube or primary peritoneal carcinoma patients who have received at least 3 prior lines of chemotherapy and who do not carry deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA) mutations.

NCT ID: NCT02028117 Recruiting - Clinical trials for Recurrent Platinum Resistant Ovarian Cancer

Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients

OCTAVE
Start date: January 2014
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a phase I/II open label clinical study in patients with platinum-resistant epithelial ovarian cancer. The Phase I part of the study will determine the dose of enadenotucirev to be recommended for further studies and will examine primarily the safety and tolerability but also the pharmacokinetics of administering enadenotucirev intraperitoneally. Once the dose of IP enadenotucirev to be used in combination with IV weekly paclitaxel has been determined, the phase II stage will begin as an open label dose expansion of that regimen. The phase II stage aims to determine whether intraperitoneal enadenotucirev has a risk benefit profile that supports further investigation in the treatment of patients with platinum-resistant epithelial ovarian Cancer.

NCT ID: NCT01653912 Unknown status - Clinical trials for Recurrent Platinum-resistant Ovarian Cancer

Dose-finding Study in Platinum-Resistant Ovarian Cancer

Start date: December 2012
Phase: Phase 1/Phase 2
Study type: Interventional

- Dose-finding study of GSK2110183 administered in combination with carboplatin and paclitaxel to any subject with recurrent ovarian cancer. - Safety and efficacy study of GSK2110183 administered in combination with carboplatin and paclitaxel to subjects with platinum-resistant ovarian cancer.